Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Therapuetic Areas:Nephrology / Urology
Age Range:Any - 21
Start Date:March 2015
End Date:October 2024
Contact:Laleh Abedinzadeh, MD

Use our guide to learn which trials are right for you!

Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant
lipoproteins including low density lipoprotein from circulating blood flow and rapidly
reduces the plasma cholesterol level. The system was originally developed for the treatment
of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied
to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring
about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g,
proteinuria and hypoproteinemia).

Although the definitive mechanism by which the system may relieve nephrotic syndrome is
unknown, it has been recognized as one of alternative therapies for refractory nephrotic
syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the
Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of

This study is conducted as a post approval study imposed by Humanitarian Device Exemption
(HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the
treatment of drug-resistant pediatric primary FSGS.

Inclusion Criteria:

- A pediatric patient is deemed suitable for inclusion in the study if the patient has
FSGS with a GFR ≥ 60 ml/min/1.73 m 2 and any of the following:

- Refractory nephrotic syndrome in which standard treatment options are
unsuccessful (i.e., patient is unresponsive to standard corticosteroid and/or
calcineurin inhibitor therapy for at least 8 weeks resulting in failure to
achieve complete or partial remission);

- Refractory nephrotic syndrome in which standard treatment options are not well
tolerated (i.e., patients intolerant to standard therapies due to severe side
effects that negatively affect quality of life without providing an acceptable
level of clinical benefit);

- Refractory or recurrent nephrotic syndrome in which standard therapy is


- Pediatric post renal transplant patients with nephrotic syndrome associated with primary

Exclusion Criteria:

- General Exclusion Criteria

- Patient is greater than 21 years of age

- Parent or patient is unwilling or unable to sign and date the informed consent
(Note: Only patients 18-21 years of age may sign the informed consent on their
own behalf)

- Pregnant, lactating, or planning to become pregnant prior to completing the study
(Note: The safety of the use of Liposorber® in pregnant women has not been
studied. There may be unknown risks to an embryo/fetus. Sexually active women of
child bearing potential should avoid pregnancy during the use of the Liposorber
device and throughout the study duration.)

- Unable or unwilling to comply with the follow-up schedule

- Simultaneously participating in another investigational drug or device study

- Body weight < 18 kg (39.7 lbs)

- Medical Exclusion Criteria

- Currently being administered ACE inhibitors that cannot be withheld for at least
24 hours prior to each apheresis treatment (Note: The time period to withhold ACE
inhibitors should be prolonged, if determined by the treating physician,
considering each individual's renal function and the biological half-life of the
ACE-inhibitor currently in use.)

- Currently being administered antihypertensive drugs other than ACE inhibitors
(e.g., Angiotensin II receptor blockers (ARBs) that cannot be withheld on the day
of apheresis until after the procedure

- Medical condition or disorder that would limit life expectancy to less than the
primary clinical study endpoint or that may cause noncompliance with the study
plan or confound the data analysis

- Hypersensitivity to dextran sulfate, heparin, or ethylene oxide

- Adequate anticoagulation cannot be achieved due to severe hemophilia, severe
hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of
vitamin K antagonist medications

- Extracorporeal circulation therapy with Liposorber® LA-15 System cannot be
tolerated due to severe cardiac insufficiency, acute myocardial infarction,
severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or
severe uncontrollable hypotension

- Cardiac impairments such as uncontrolled arrhyth¬mia, unstable angina,
decompensated congestive heart failure, or valvular disease

- Thyroid disease or liver abnormalities

- Unresolved systemic or local infection that could affect the clinical study
We found this trial at
1 Perkins Square
Akron, Ohio 44308
(330) 543-1000
Phone: 330-543-8950
Akron Children's Hospital From humble beginnings as a day nursery in 1890, Akron Children
Akron, OH
Click here to add this to my saved trials
Charleston, SC
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Grand Rapids, MI
Click here to add this to my saved trials
Loma Linda, California 92354
Loma Linda, CA
Click here to add this to my saved trials
Orlando, Florida 32827
Phone: 407-650-7715
Orlando, FL
Click here to add this to my saved trials
Richmond, Virginia 23298
Phone: 804-628-5853
Richmond, VA
Click here to add this to my saved trials
Wilmington, Delaware 19803
Phone: 302-651-5527
Wilmington, DE
Click here to add this to my saved trials